Myocarditis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Myocarditis - Pipeline Review, H2 2014', provides an overview of the Myocarditis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocarditis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocarditis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Myocarditis Overview 6 Therapeutics Development 7 Pipeline Products for Myocarditis - Overview 7 Pipeline Products for Myocarditis - Comparative Analysis 8 Myocarditis - Therapeutics under Development by Companies 9 Myocarditis - Therapeutics under Investigation by Universities/Institutes 10 Myocarditis - Pipeline Products Glance 11 Early Stage Products 11 Myocarditis - Products under Development by Companies 12 Myocarditis - Products under Investigation by Universities/Institutes 13 Myocarditis - Companies Involved in Therapeutics Development 14 CEL-SCI Corporation 14 Novartis AG 15 Myocarditis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Molecule Type 21 Drug Profiles 23 CEL-1000 - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Cell Therapy to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Cell Therapy to Target Flt3L for Autoimmune Myocarditis - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 OBR-5340 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Myocarditis - Dormant Projects 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Number of Products under Development for Myocarditis, H2 2014 7 Number of Products under Development for Myocarditis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Products under Investigation by Universities/Institutes, H2 2014 13 Myocarditis - Pipeline by CEL-SCI Corporation, H2 2014 14 Myocarditis - Pipeline by Novartis AG, H2 2014 15 Assessment by Monotherapy Products, H2 2014 16 Number of Products by Stage and Target, H2 2014 18 Number of Products by Stage and Mechanism of Action, H2 2014 20 Number of Products by Stage and Molecule Type, H2 2014 22 Myocarditis - Dormant Projects, H2 2014 30
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.